Search Result

Results for "

tachycardia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (6) Angiotensin-converting Enzyme (ACE) (1) Calcium Channel (6) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (1) Potassium Channel (5) Sodium Channel (3)
By Research Areas:	Cancer (1) Cardiovascular Disease (20) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119850

Aladorian ARM036	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036) is a benzothiazepine derivative, with anti-arrhythmia effect. Aladorian is a ryanodine receptor (RyR2) blocker. Aladorian is used for the research of heart failure and catecholaminergic polymorphic ventricular tachycardia .

HY-W010950

Flecainide 2 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-W010950A

Flecainide hydrochloride 2 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .

HY-B1392A

Esmolol	Adrenergic Receptor	Cardiovascular Disease
Esmolol is a potent and cardio-selective β-adrenergic blocker. Esmolol shows cardioprotection. Esmolol has the potential for the research of tachycardia with ischemic heart disease .

HY-119850A

Aladorian sodium ARM036 sodium	Calcium Channel	Cardiovascular Disease
Aladorian (ARM036) sodium is a benzothiazepine derivative, with anti-arrhythmia effect. Aladorian sodium is a ryanodine receptor (RyR2) blocker. Aladorian sodium is used for the research of heart failure and catecholaminergic polymorphic ventricular tachycardia .

HY-167902

YM-31636 free base	5-HT Receptor	Metabolic Disease
YM-31636 free base is an orally active, potent and selective 5-HT₃ receptor agonist with a K_i value of 0.2 nM. YM-31636 free base induces contraction of isolated guinea pig distal colon. YM-31636 free base induces tachycardia with the relative intrinsic activity of approximately 0.23 in isolated guinea pig right atrium. YM-31636 free base is promising for research of constipation .

HY-W010950R

Flecainide (Standard)	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-113695

BW A575C	Angiotensin-converting Enzyme (ACE) Adrenergic Receptor	Cardiovascular Disease
BW A575C is a dual inhibitor against angiotensin converting enzyme (ACE) and β-adrenoceptor. BW A575C produces a competitive blockade of Isoprenaline (HY-108353)-induced tachycardia in a guinea-pig right atrial. BW A575C also inhibits Angiotensin I (HY-P1032)-induced pressor responses in rats. BW A575C is promising for research of hypertensive diseases .

HY-116759

VU0405601	Potassium Channel	Cardiovascular Disease
VU0405601 is a potent KV11.1 channel activator. VU0405601 protects cardiac tissue from dofetilide (HY-B0232)-induced ventricular tachycardia .

HY-108582

Y-27152	Potassium Channel	Cardiovascular Disease
Y-27152, a proagent of the K_ATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state .

HY-124883

R-(–)-Flecainide	Drug Isomer	Cardiovascular Disease
R-(–)-Flecainide is an orally active antiarrhythmic agent, which inhibits ventricular ectopic activity .

HY-111018

FPL 62129	Calcium Channel	Cardiovascular Disease
FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator .

HY-101222

SB-203186 hydrochloride	5-HT Receptor	Cardiovascular Disease Neurological Disease
SB-203186 hydrochloride is a potent, selective and competitive 5-HT₄ antagonist. SB-203186 hydrochloride antagonizes the 5-HT₄ receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pK_B values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively .

HY-17611A1

Etripamil hydrochloride MSP-2017 hydrochloride; (-)-MSP-2017 hydrochloride	Calcium Channel	Neurological Disease
Etripamil (MSP-2017) hydrochloride is a short-acting, L-type calcium channel antagonist that can be used in the study of paroxysmal supraventricular tachycardia (PSVT). Etripamil hydrochloride inhibits calcium influx through slow calcium channels, thereby slowing atrioventricular node conduction and prolonging the atrioventricular node refractory period.

HY-113322

3-Hydroxyquinine 3-Hydroxyquinidine	Drug Metabolite	Cardiovascular Disease
3-Hydroxyquinine is a metabolite of Quinidine (HY-B1751). 3-Hydroxyquinine prevents ventricular fibrillation and ventricular tachycardia after coronary reperfusion in an isolated rat heart reperfusion arrhythmia model in a concentration-dependent manner. 3-Hydroxyquinine can be used in the study of cardiac arrhythmias .

HY-14304A

Zinterol hydrochloride 1 Publications Verification MJ 9184 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist . Zinterol hydrochloride increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM . Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits .

HY-14304

Zinterol MJ 9184	Adrenergic Receptor	Cardiovascular Disease
Zinterol (MJ 9184) is a potent and selective β2-adrenoceptor agonist . Zinterol increases I_Ca in a concentration-dependent manner with an EC₅₀ of 2.2 nM .

HY-101172

RS 23597-190 EP-A-501322	5-HT Receptor	Cardiovascular Disease
RS 23597-190 (EP-A-501322) is a high affinity and selective 5-HT4 receptor antagonist. RS 23597-190 inhibits 5-HT (HY-B1473A)-induced tachycardia. RS 23597-190 significantly inhibits superoxide production in high glucose .

HY-157655

Cafedrine-theodrenaline	Adrenergic Receptor	Cardiovascular Disease
Cafedrine-theodrenaline can stimulate the cardiovascular system through β-adrenergic receptor mediation, increasing arterial pressure, stroke volume, and cardiac output, while reducing peripheral vascular resistance, thereby supporting overall cardiac function. Cafedrine-theodrenaline helps maintain blood pressure during hypotensive episodes without causing significant tachycardia .

HY-17611

Etripamil MSP-2017; (-)-MSP-2017	Calcium Channel	Cardiovascular Disease
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells .

HY-116500A

AH-1058	Calcium Channel	Cardiovascular Disease
AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes.

HY-119200

LY-195448 hydrochloride	Endogenous Metabolite	Cancer
LY-195448 hydrochloride is a phenethanolamine that exhibits anti-tumour activity across various murine tumour models. LY-195448 hydrochloride acts by blocking cells at metaphase. LY-195448 hydrochloride has demonstrated a lack of "standard" side effects commonly associated with cancer treatments, such as myelosuppression and gastrointestinal toxicity. LY-195448 hydrochloride was evaluated in a phase I trial, where it showed only mild and reversible side effects like hypotension, tachycardia, and tremor.

HY-116790B

(±)-Penbutolol (Rac)-Penbutolol; (±)-Isopenbutolol	Adrenergic Receptor	Cardiovascular Disease
(±)-Penbutolol ((Rac)-Penbutolol) is the racemic mixture of Penbutolol. (±)-Penbutolol is an orally active β-adrenergic receptor antagonist. (±)-Penbutolol antagonizes exercise-induced tachycardia, reduces the increase in peak expiratory flow rate (PEFR) caused by exercise, and decreases resting plasma renin activity (PRA). (±)-Penbutolol reaches peak plasma concentration 1 hour after oral administration, with a half-life of 4.5 hours, and is converted into an active metabolite in the body. (±)-Penbutolol can be used in cardiovascular-related disease research .

Cat. No.	Product Name	Target	Research Area

HY-P5494

DPc10	Peptides	Others
DPc10 is a biological active peptide. (This is amino acids 2460 to 2495 fragment of cardiac ryanodine receptor (RyR2). RyR2 controls calcium release from the sarcoplasmic reticulum, which begins muscle contraction. Mutated RyR2 is associated to ventricular tachycardia (VT) and sudden death.)

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.